Hard NAPLEX Oncology Therapeutics Practice Questions

Mastering oncology is a critical component of your NAPLEX Prep, as it requires a deep understanding of complex dosing, toxicities, and supportive care strategies. To excel, you must go beyond basic drug names and focus on clinical decision-making, such as managing extravasation, calculating chemotherapy doses, and identifying oncologic emergencies. This guide provides hard NAPLEX oncology therapeutics practice questions designed to simulate the rigor of the actual board exam.

Concept Explanation

Oncology therapeutics involves the clinical application of cytotoxic chemotherapy, targeted biological agents, and immunotherapy to treat various cancers while managing treatment-induced toxicities. This field is governed by precise dosing protocols, often based on Body Surface Area (BSA) using the Mosteller formula: $$\text{BSA (m}^2) = \sqrt{\frac{ \text{Height (cm)} \times \text{Weight (kg)}}{3600}}$$ or the Calvert formula for Carboplatin dosing: $$\text{Dose (mg)} = \text{Target AUC} \times ( \text{GFR} + 25)$$. Beyond calculations, oncology practice requires a mastery of "Black Box Warnings," such as the cardiotoxicity of anthracyclines or the pulmonary toxicity of bleomycin. Pharmacists play a pivotal role in supportive care, which include managing chemotherapy-induced nausea and vomiting (CINV) based on the emetogenic potential of the regimen as defined by NCCN Guidelines. Understanding the timing of rescue agents, such as leucovorin for methotrexate or mesna for cyclophosphamide, is essential for patient safety.

Solved Examples

1. Carboplatin Dosing: A 65-year-old female (Weight: 70 kg, Height: 165 cm, Serum Creatinine: 1.2 mg/dL) is to receive Carboplatin at a target AUC of 5. Calculate the dose.

   1. First, calculate CrCl using Cockcroft-Gault: $$\text{CrCl} = \frac{(140 - 65) \times 70}{72 \times 1.2} \times 0.85 \approx 51.7 \text{ mL/min}$$.

   2. Apply the Calvert Formula: $$\text{Dose} = 5 \times (51.7 + 25)$$.

   3. Calculation: $$5 \times 76.7 = 383.5 \text{ mg}$$.

   4. Rounding to the nearest whole number, the dose is 384 mg.

2. Extravasation Management: A patient receiving Vincristine develops sudden pain and swelling at the IV site. What is the appropriate management?

   1. Stop the infusion immediately but do not remove the needle yet to attempt aspiration of the drug.

   2. Vinca alkaloids require warm compresses to promote vasodilation and drug dispersion.

   3. Apply the antidote Hyaluronidase if available per institutional protocol.

   4. Contrast this with anthracyclines, which require cold compresses and Dexrazoxane (Totect).

3. CINV Prophylaxis: A patient is starting a HEC (Highly Emetogenic Chemotherapy) regimen consisting of Cisplatin and Fluorouracil. Outline the standard 4-drug prophylaxis.

   1. NK1 Receptor Antagonist (e.g., Aprepitant or Fosaprepitant).

   2. 5-HT3 Receptor Antagonist (e.g., Ondansetron or Palonosetron).

   3. Dexamethasone.

   4. Olanzapine (now recommended in many guidelines for HEC).

Practice Questions

1. A patient with a history of heart failure (LVEF 40%) is diagnosed with breast cancer. Which of the following agents should be avoided or used with extreme caution due to its cumulative lifetime dose limit of $450 \text{–}550 \text{ mg/m}^2$?

2. Calculate the BSA for a male patient who is 5'11" tall and weighs 195 lbs. Use the Mosteller formula.

3. A patient receiving high-dose Methotrexate (> 500 \text{ mg/m}^2) has a 24-hour methotrexate level that is significantly higher than the safety threshold. Which agent must be administered to provide a source of reduced folate?

4. Which medication is specifically indicated for the treatment of hyperuricemia associated with Tumor Lysis Syndrome (TLS) when allopurinol is insufficient or contraindicated due to high urate burden?

5. A patient is prescribed Irinotecan. They experience acute, severe diarrhea and diaphoresis during the infusion. Which medication should be administered immediately to treat this cholinergic reaction?

6. Tamoxifen is a prodrug metabolized by which major CYP enzyme to its most active metabolite, endoxifen?

7. A patient is receiving a regimen containing Bleomycin. Which baseline and periodic diagnostic test is mandatory to monitor for drug-induced toxicity?

8. Which monoclonal antibody requires screening for KRAS mutations, as it is only effective in patients with "wild-type" KRAS colorectal cancer?

9. A pharmacist is preparing an IV bag of Paclitaxel. What specific type of IV tubing and container must be used for this taxane?

10. What is the maximum individual dose of Vincristine usually recommended to prevent severe peripheral neuropathy?

Answers & Explanations

1. Doxorubicin: This anthracycline is associated with irreversible dose-related cardiotoxicity. Patients with pre-existing low LVEF are at high risk. You can find more details in our NAPLEX Oncology Therapeutics Practice Questions with Answers.

2. 2.13 $\text{m}^2$: Convert height to cm (180.34) and weight to kg (88.45). $$\sqrt{\frac{180.34 \times 88.45}{3600}} = \sqrt{4.43} \approx 2.10 \text{–}2.13 \text{ m}^2$$ depending on rounding during steps.

3. Leucovorin (Folinic Acid): It bypasses the inhibited dihydrofolate reductase enzyme to replenish the folate pool. Glucarpidase may also be used if levels are extremely high and renal failure is present.

4. Rasburicase: Unlike allopurinol, which prevents uric acid formation, rasburicase is a recombinant urate oxidase enzyme that converts existing uric acid into allantoin, which is highly soluble and easily excreted.

5. Atropine: Irinotecan can cause an acute cholinergic syndrome (diarrhea, sweating, salivation). Atropine is the treatment of choice for acute symptoms, while loperamide is used for delayed diarrhea.

6. CYP2D6: Inhibitors of CYP2D6 (like fluoxetine or paroxetine) can decrease the efficacy of tamoxifen by preventing its conversion to endoxifen.

7. Pulmonary Function Tests (PFTs): Specifically, the DLCO (diffusing capacity of the lungs for carbon monoxide) is monitored for bleomycin-induced pulmonary fibrosis.

8. Cetuximab (Erbitux): Patients with KRAS mutations do not respond to EGFR inhibitors like cetuximab or panitumumab in colorectal cancer.

9. Non-PVC container and 0.22-micron filter: Paclitaxel contains Cremophor EL, which can leach DEHP from standard PVC bags. Filtering is required to remove precipitates.

10. 2 mg: Regardless of the calculated BSA dose, vincristine is capped at 2 mg per dose to minimize the risk of debilitating neurotoxicity.

1. Which agent is used as a "rescue" to prevent hemorrhagic cystitis in patients receiving high-dose cyclophosphamide or ifosfamide?

• ADexrazoxane
• BMesna
• CAmifostine
• DLeucovorin

Frequently Asked Questions

What is the difference between Adjuvant and Neoadjuvant therapy?

Neoadjuvant therapy is administered before the primary treatment (usually surgery) to shrink a tumor, while adjuvant therapy is given after the primary treatment to eradicate any remaining microscopic disease and reduce the risk of recurrence.

How do you calculate the Absolute Neutrophil Count (ANC)?

The ANC is calculated by multiplying the total White Blood Cell (WBC) count by the percentage of neutrophils (segmented neutrophils plus bands). Use the formula: $$\text{ANC} = \text{WBC} \times \frac{(\% \text{Segs} + \% \text{Bands})}{100}$$.

Why is Vincristine never administered intrathecally?

Intrathecal administration of vincristine is fatal, as it causes progressive ascending myeloencephalopathy; it must only be administered intravenously, often in a small volume minibag to prevent accidental spinal injection.

What is the role of Mesna in chemotherapy?

Mesna acts as a chemoprotectant by binding to acrolein, a toxic metabolite of ifosfamide and cyclophosphamide that accumulates in the bladder, thereby preventing hemorrhagic cystitis. For more on drug-induced toxicities, see our Hard NAPLEX Oncology Pharmacology Practice Questions.

When should G-CSF (e.g., Filgrastim) be administered?

Granulocyte colony-stimulating factors are typically administered 24 to 72 hours after the completion of chemotherapy to reduce the duration and severity of neutropenia, but they should never be given within 24 hours before or after chemo.

Practice real clinical decision-making.

Improve therapeutic reasoning with pharmacy patient cases and scenario-based NAPLEX questions.

Practice Patient Cases